Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge

被引:23
|
作者
Veltri, RW
Miller, MC
Mangold, LA
O'Dowd, GJ
Epstein, JI
Partin, AW
机构
[1] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21205 USA
[2] Immunicon Corp, Huntingdon, PA USA
[3] UroCor Inc, Oklahoma City, OK USA
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 01期
关键词
prostate; prostatic neoplasms; prostate-specific antigen; tumor markers; biological; neoplasm staging;
D O I
10.1016/S0022-5347(05)64839-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We developed an algorithm for predicting the likelihood of organ confined disease in patients with clinical stage T1c prostate cancer using biopsy pathology, computer assisted image analysis and serum prostate specific antigen (PSA). Materials and Methods: Of the 557 consecutive men enrolled in this study between October 1998 and January 2000 scheduled for radical prostatectomy at a single institution 386 (69%) presented with clinical stage T1c disease. Study exclusion criteria included neoadjuvant hormonal treatment with luteinizing hormone-releasing hormone, antiandrogen or 5alpha-reductase inhibitors. Preoperative serum, biopsy histology slides, clinical demographic information, prostatectomy pathology and prostate weight data were obtained. Biomarkers assessed included total PSA, complexed PSA, free PSA, the free-to-total PSA ratio, quantitative nuclear grade determined by image analysis, complexed PSA density, and biopsy Gleason grade and score. To determine patient specific quantitative nuclear grade values, images from approximately 125 cancer nuclei were captured per patient from the area of the biopsy section with the highest Gleason score. The variance in 60 nuclear size, shape and chromatin texture descriptors was calculated for each gallery of nuclei. Logistic regression was done to determine the most accurate combination of variables for predicting organ confined prostate cancer. Results: Complete results and data were available on 255 of the 386 men (66%) with an average age plus or minus standard deviation of 58.8 +/- 6 years who had stage T1c disease, including 49 (19%) with pathologically nonorgan confined disease. Logistic regression analysis revealed that quantitative nuclear grade, biopsy Gleason score, total PSA, the calculated free-to-total PSA ratio, complexed PSA and complexed PSA density were univariately significant for predicting organ confined disease (p < 0.05). On backward stepwise logistic regression only quantitative nuclear grade, complexed PSA density and Gleason score remained in a model yielding an area under the receiver operating characteristics curve of 82.4%. Conclusions: The quantitative nuclear grade biomarker was the strongest independent predictor of pathological stage in men with clinical stage T1c prostate cancer when combined with biopsy Gleason score and complexed PSA density data.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 50 条
  • [1] PATHOLOGICAL CHARACTERISTICS OF NONPALPABLE PROSTATE-CANCER (STAGE T1C)
    CHANEY, TL
    JENNINGS, S
    AUSTENFELD, MS
    GARCIA, FU
    LABORATORY INVESTIGATION, 1994, 70 (01) : A71 - A71
  • [2] Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate
    Carter, HB
    Epstein, JI
    WORLD JOURNAL OF UROLOGY, 1997, 15 (06) : 359 - 363
  • [3] MANAGEMENT OF STAGE T1C PROSTATE-CANCER
    GIBBONS, RP
    CANCER, 1995, 75 (07) : 1900 - 1902
  • [4] Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis
    Lerner, SE
    Seay, TM
    Blute, ML
    Bergstralh, EJ
    Barrett, D
    Zincke, H
    JOURNAL OF UROLOGY, 1996, 155 (03): : 821 - 826
  • [5] Ultrasound findings are not useful for defining stage T1c prostate cancer
    Sanders, H
    El-Galley, R
    WORLD JOURNAL OF UROLOGY, 1997, 15 (06) : 336 - 338
  • [6] Active surveillance as a treatment option for stage T1c prostate cancer
    Kakehi, Yoshiyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2007, 14 (12) : 1121 - 1121
  • [7] Stratification of stage T1c prostate cancer to predict biochemical recurrence
    Gretzer, MB
    Epstein, JI
    Pound, CR
    Walsh, PC
    Partin, AW
    JOURNAL OF UROLOGY, 2002, 167 (04): : 223 - 223
  • [8] Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer
    Ramos, CG
    Carvalhal, GF
    Smith, DS
    Mager, DE
    Catalona, WJ
    JOURNAL OF UROLOGY, 1999, 161 (05): : 1525 - 1529
  • [9] Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial
    Southwick, PC
    Catalona, WJ
    Partin, AW
    Slawin, KM
    Brawer, MK
    Flanigan, RC
    Patel, A
    Richie, JP
    Walsh, PC
    Scardino, PT
    Lange, PH
    Gasior, GH
    Parson, RE
    Loveland, KG
    JOURNAL OF UROLOGY, 1999, 162 (04): : 1346 - 1351
  • [10] Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial - Comment
    Crawford, ED
    JOURNAL OF UROLOGY, 1999, 162 (04): : 1351 - 1351